Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction

In this open-label investigation, the pharmacokinetics of rifapentine and its active metabolite, 25-desacetyl-rifapentine, were characterized in patients with varying degrees of hepatic dysfunction. Eight patients with mild-to-moderate chronic, stable hepatic dysfunction and seven patients with moderate-to-severe hepatic dysfunction received single oral 600-mg doses of rifapentine. Maximum plasma concentration of rifapentine was lower, time to maximum plasma concentration (tmax) was greater, and elimination half-life (t 1/2) was longer in the patients with moderate-to-severe hepatic dysfunction than in those with mild-to-moderate dysfunction. However, mean area under the concentration-time curve extrapolated to infinity (AUC0-infinity) for the two groups was similar. AUC0-infinity values in patients with hepatic dysfunction were 19% to 25% higher than values previously reported for healthy volunteers. The 25-desacetyl metabolite appeared in plasma slowly after the single oral dose of rifapentine. Similar to findings for the parent drug, comparable plasma exposures of 25-desacetyl-rifapentine based on AUC0-infinity were found in the two groups of patients with mild-to-moderate and moderate-to-severe hepatic dysfunction. Rifapentine was well tolerated in this patient population, irrespective of the etiology or severity of hepatic dysfunction. These safety and pharmacokinetic results suggest that no dosage adjustments for rifapentine are needed in patients with hepatic impairment.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Langdon, J. Wilkins, L. McFadyen, H. McIlleron, P. Smith, and U. S. H. Simonsson Population Pharmacokinetics of Rifapentine and Its Primary Desacetyl Metabolite in South African Tuberculosis Patients Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4429 - 4436. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				J. E. Conte Jr., J. A. Golden, M. McQuitty, J. Kipps, E. T. Lin, and E. Zurlinden Single-Dose Intrapulmonary Pharmacokinetics of Rifapentine in Normal Subjects Antimicrob. Agents Chemother., April 1, 2000; 44(4): 985 - 990. [Abstract] [Full Text]